Author:Arvid Söderhäll

Empros first clinical trial published

Empros first clinical trial, closed in 2017 was recently published in Obesity Science and Practice, see full text article here. In this phase 2a trial Empros compared three different doses of EMP16 to Xenical. The trial demonstrated that EMP16 is safe and has an improved...

0
0

Empros Pharma tar in 40 MSEK och säkrar finansieringen av proof-of-concept-studie för EMP16

Det svenska läkemedelsutvecklingsföretaget Empros Pharma AB tar nu nästa steg i den kliniska utvecklingen av läkemedelskandidaten för viktminskning, EMP16. Empros har tillsammans med Vator Securities rest 40 miljoner kronor i en fulltecknad aktieemission för att finansiera en proof-of-concept-studie. Studien som planeras är en sex månaders...

0
0

Empros Pharma participates in Bio Korea

CEO Arvid Söderhäll participated in at the Bio-Korea conference in Seoul in May. South Korea represents a vibrant region with an impressive traction. Empros Pharma has established contacts with investors, pharmaceutical industry, key opinion leaders, regulatory authority as well as consultants....

0
5

Pressrelease Phase 2a trial

Swedish Start-Up Pharma reveals positive Phase 2a trial - results from a novel oral medication treatment of obesity  The Swedish Pharmaceutical start-up Empros Pharma AB has new clinical results from a Phase 2a trial of its first novel and unique product EMP16; an oral drug for...

0
1